Pay in 4 interest-free payments of $5.81 Learn more
Ships within 48 hours · Estimated delivery Sep 14 - Sep 19
Tashiro Y, Sato K, Watanabe T, Nohtomi K, Terasaki M, Nagashima M, et al
Forschung & Entwicklung Unsere F&E Prinzipien Jedes Produkt, das wir herstellen, besteht drei fundamentale Prinzipien ohne Ausnahme
"Is use of vitamin K antagonists associated with the risk of prostate cancer?: A meta-analysis"
The Denmark-based company announced Wednesday it had received a Complete Response Letter for dasiglucagon, which it was proposing for the ultra-rare genetic disease congenital hyperinsulinism, due to the timing of a third-party manufacturing facility reinspection. In an initial visit, the FDA had flagged deficiencies in a third-party contract manufacturer, which the company claims had been resolved by the time of a reinspection in August/September 2024
US$ 26.72
US$ 26.82
US$ 26.93
US$ 29.15
US$ 26.55
US$ 28.34
US$ 24.41
US$ 20.38
US$ 23.93
US$ 25.18
